Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Asset Allocation Committee Outlook 2Q21

The Temperature’s Rising

The first quarter of 2021 brought what the Asset Allocation Committee expected, and as it looks to the next six to
12 months, it faces two questions. Do we think the economy will overheat, pushing bond yields to levels that unsettle equity markets or even force central banks to stifle the recovery? And have markets moved enough to justify some rebalancing of last quarter’s views?

Download the full paper here

 

1 Comments
Paul Hocking
July 02, 2021

Cannot access this document are we able to fix this at all. Thanks

 

Leave a Comment:


banner

Sponsors

© 2024 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. To the extent any content is general advice, it has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.